Pharmafile Logo

lenalidomide

- PMLiVE

Celgene’s Revlimid cleared for aggressive lymphoma type in EU

Analysts anticipate sales of up to $10bn for the newly-expanded drug in coming years

- PMLiVE

Takeda partners with Marvel for IBD superheroes

Will work with the entertainment firm's content marketing agency

- PMLiVE

Amgen’s Kyprolis wins new indication in Europe

Regulators have handed the treatment a less restrictive licence in multiple myeloma 

- PMLiVE

Takeda hands back rights to two Amgen drugs

Returns pain and ovarian cancer candidates but will continue with collaboration

- PMLiVE

Takeda starts trial of norovirus vaccine

If approved the drug is anticipated to surpass sales of GSK’s Rotarix vaccine

- PMLiVE

Takeda forms new women’s health and cancer company

Recruits former Medivation CMO Lynn Seely to lead Myovant Sciences

Takeda appoints chief financial officer and corporate officer

James Kehoe takes on both roles from 15 June

- PMLiVE

J&J gets European OK for myeloma therapy Darzalex

First-in-class immunotherapy achieved ‘significant increase’ in overall survival

UK Life Sciences Strategy - one year on

Astellas, Daiichi Sankyo and Takeda to study biomarkers

Collaboration aims to establish comprehensive database to accelerate drug development

- PMLiVE

Teva and Takeda appoint head of Japanese generics venture

Hiroshi Matsumori will lead partnership of Teva’s generics portfolio and Takeda brands

- PMLiVE

Focus on multiple myeloma treatment: Witnessing a transformation

Consultant David Cooney of Blue Latitude Health will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.

Blue Latitude Health

- PMLiVE

Forging a path in specialty care

Takeda’s Marc Princen on the company’s plans to build a reputation in oncology, gastroenterology and vaccine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links